Given its correlation with stromal cells, we can infer that the prognostic benefit of low MGAT1 expression in pancreatic cancer patients is likely more related to its impact on stromal cells rather than immune cells (Figures 9B, C). Here, MGAT1 is linked to pancreatic neoplasm.